- Home
- GDHG vs NERV Comparison
GDHG vs NERV Comparison
Compare GDHG & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDHG
- NERV
- Stock Information
- Founded
- GDHG 2008
- NERV 2007
- Country
- GDHG China
- NERV United States
- Employees
- GDHG N/A
- NERV N/A
- Industry
- GDHG Services-Misc. Amusement & Recreation
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- GDHG Consumer Discretionary
- NERV Health Care
- Exchange
- GDHG Nasdaq
- NERV Nasdaq
- Market Cap
- GDHG 11.0M
- NERV 10.3M
- IPO Year
- GDHG 2023
- NERV 2014
- Fundamental
- Price
- GDHG $0.29
- NERV $1.76
- Analyst Decision
- GDHG
- NERV Hold
- Analyst Count
- GDHG 0
- NERV 1
- Target Price
- GDHG N/A
- NERV $5.00
- AVG Volume (30 Days)
- GDHG 2.5M
- NERV 18.7K
- Earning Date
- GDHG 04-29-2025
- NERV 05-05-2025
- Dividend Yield
- GDHG N/A
- NERV N/A
- EPS Growth
- GDHG N/A
- NERV N/A
- EPS
- GDHG N/A
- NERV 0.19
- Revenue
- GDHG $22,333,251.00
- NERV N/A
- Revenue This Year
- GDHG N/A
- NERV N/A
- Revenue Next Year
- GDHG N/A
- NERV N/A
- P/E Ratio
- GDHG N/A
- NERV $9.21
- Revenue Growth
- GDHG N/A
- NERV N/A
- 52 Week Low
- GDHG $0.25
- NERV $1.15
- 52 Week High
- GDHG $19.00
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- GDHG 37.54
- NERV 58.11
- Support Level
- GDHG $0.26
- NERV $1.66
- Resistance Level
- GDHG $0.35
- NERV $1.81
- Average True Range (ATR)
- GDHG 0.06
- NERV 0.16
- MACD
- GDHG -0.02
- NERV 0.04
- Stochastic Oscillator
- GDHG 16.52
- NERV 92.42
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.